Concepedia

Author

Virginia Albiñana

Centro de Investigaciones Biológicas Margarita Salas

Also Known As

V. Albiñana, Virginia Albinana, Virginia Albiñana

38

Publications

658

Citations

15

H-Index

34

Concepts

All Affiliations

Centro de Investigaciones Biológicas Margarita SalasCentro de Investigación Biomédica en RedCentre for Biomedical Network Research on Rare DiseasesHospital Universitario Fundación Jiménez DíazInstituto de Salud Carlos III
VA

About

Virginia Albiñana is an author at Centro de Investigaciones Biológicas Margarita Salas specializing in molecular signaling, medicine, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

43

2

Immunology

2

2

43

3

Health Sciences

1

1

29

4

Cell Biology

1

1

14

5

Molecular Medicine

1

1

29

Virginia Albiñana

×

16

Publications

497

Citations

12

H-Index

YearCitations

Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells

Virginia Albiñana, Maria Bernabeu-Herrero, Roberto Zarrabeitia,

Thrombosis and Haemostasis

2010

83

Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia

Virginia Albiñana, Lucía Recio-Poveda, Roberto Zarrabeitia,

Thrombosis and Haemostasis

2012

57

Immunosuppressor FK506 Increases Endoglin and Activin Receptor-Like Kinase 1 Expression and Modulates Transforming Growth Factor-β1 Signaling in Endothelial Cells

Virginia Albiñana, Francisco Sanz‐Rodríguez, Lucía Recio-Poveda,

Molecular Pharmacology

2011

56

Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients

Virginia Albiñana, Karina Villar Gómez de las Heras, Gemma Serrano‐Heras,

Orphanet Journal of Rare Diseases

2015

51

Mutation study of Spanish patients with Hereditary Hemorrhagic Telangiectasia

Ana Fontalba, Africa Fernández-L, Eva García‐Alegría,

BMC Medical Genetics

2008

37

Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease

Virginia Albiñana, Rosa María Jiménez Escribano, Isabel Soler,

Orphanet Journal of Rare Diseases

2017

35

Mutation affecting the proximal promoter of Endoglin as the origin of hereditary hemorrhagic telangiectasia type 1

Virginia Albiñana, María Paz Zafra, Jorge Colau,

BMC Medical Genetics

2017

32

Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia

Roberto Zarrabeitia, Luisa Ojeda‐Fernández, Lucia Recio,

Thrombosis and Haemostasis

2016

29

The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease

Ángel M. Cuesta, Virginia Albiñana, Eunate Gallardo‐Vara,

Scientific Reports

2019

25

Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: phase III clinical trial

Beatriz González-Rodríguez, Karina Villar Gómez de las Heras, Daniel T. Aguirre,

BMJ Open Ophthalmology

2019

18

Page 1